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Abstract Epigallocatechin gallate (EGCG), a major compo-
nent of green tea, has been previously shown to inhibit platelet
aggregation. The e¡ects of other green tea catechins on platelet
function are not known. Pre-incubation with EGCG concentra-
tion-dependently inhibited thrombin-induced aggregation and
phosphorylation of p38 mitogen-activated protein kinase and
extracellular signal-regulated kinases-1/2. In contrast EGCG
stimulated tyrosine phosphorylation of platelet proteins, includ-
ing Syk and SLP-76 but inhibited phosphorylation of focal ad-
hesion kinase. Other catechins did not inhibit platelet aggrega-
tion. Interestingly, when EGCG was added to stirred platelets, a
tyrosine kinase-dependent stimulation of platelet aggregation
was observed. The two other catechins containing a galloyl
group in the 3P position (catechin gallate, epicatechin gallate)
also stimulated platelet aggregation, while catechins without a
galloyl group (catechin, epicatechin) or the catechin with a gal-
loyl group in the 2P position (epigallocatechin) did not.
0 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Flavonoids are polyphenolic compounds of plant origin [1].
Catechins (catechin, C; epicatechin, EC; epigallocatechin,
EGC; catechin gallate, CG; epicatechin gallate, ECG; epigal-
locatechin gallate, EGCG) are the main £avonoid components
of green tea [2]. Several epidemiological studies have sug-
gested that regular intake of £avonoids reduces the risk of
coronary artery disease [3,4]. These bene¢cial e¡ects can be
partially explained by the antioxidative actions of the com-
pounds [5^10]. Flavonoids have also been shown to reduce
elevated blood pressure [11], to stimulate endothelium-depen-
dent vasodilatation [12], and to inhibit tyrosine phosphoryla-
tion of the platelet-derived growth factor (PDGF) L receptor,
resulting in inhibition of vascular smooth muscle cell prolif-
eration [13^15]. In addition, inhibition of platelet function by
£avonoids may contribute to their anti-atherosclerotic e¡ects
[16]. For example, EGCG has been shown to inhibit platelet
aggregation [17,18]. These e¡ects were explained by an inhi-
bition of cytoplasmic calcium increase [18]. However, high
(millimolar) concentrations of EGCG were used and no sys-
tematic investigation of the e¡ects of various green tea cate-
chins on platelet function is available.
The present study provides evidence for complex (inhibitory
and stimulatory) e¡ects of catechins on platelet function. A
marked inhibition of thrombin-induced platelet aggregation
was only observed with EGCG and may involve an inhibition
of platelet activation. Interestingly, proaggregatory activating
e¡ects of catechins containing a galloyl group in the 3P posi-
tion were also observed that may involve a stimulation of
tyrosine phosphorylation.
2. Materials and methods
2.1. Preparation of washed platelets and platelet aggregation
Platelet-rich plasma was prepared from bu¡y coats by centrifuga-
tion at 250Ug and room temperature for 10 min. Platelets were
washed as previously described [20] and were resuspended in
HEPES-bu¡ered Tyrode bu¡er (pH 7.4) containing 2 mmol/l Ca2þ.
Catechins were pre-incubated for 30 min at 37‡C if not otherwise
indicated. Platelet aggregation was measured turbidimetrically as pre-
viously described [21]. Aggregation values are given as the maximum
change in light transmission (100% was the di¡erence between washed
platelets and bu¡er).
2.2. Flow cytometry
Expression of CD62P, CD63 and CD40L was measured by £ow
cytometry as previously described [22].
2.3. Immunoprecipitation and Western blotting
For immunoprecipitation, platelets were lysed in 2U RIPA bu¡er
(1U : 50 mM Tris^HCl, 150 mM NaCl, 1 mM EDTA, 0.4% deoxy-
cholate, 1% Nonidet P-40, pH 8.0) supplemented with protease inhib-
itors (mammalian protease inhibitor cocktail, Sigma, Deisenhofen,
Germany, 1% phenylmethylsulfonyl £uoride of a saturated solution
in ethanol). After a pre-clear with 50 Wl of a 50/50 (v/v) slurry of
protein A agarose (Amersham Pharmacia Biotech, Freiburg, Ger-
many) in phosphate-bu¡ered saline (PBS) for 2 h at 4‡C, proteins
were incubated with antibodies (5 Wg) on a rotating device overnight
at 4‡C and precipitated with 50 Wl of a 50/50 (v/v) slurry of protein A
agarose in PBS on a rotating device for 2 h at 4‡C. For Western
blotting, platelets were lysed in 2U lysis bu¡er (1U : 62.5 mmol/l
Tris^HCl, pH 6.8, 10% glycerol, 2% w/v sodium dodecyl sulfate
(SDS), 0.1% w/v bromophenol blue). Proteins were resolved by SDS
polyacrylamide (10%) gel electrophoresis, blotted and probed with
antibodies as previously described [23]. Densitometric analysis was
performed using a calibrated scanner densitometer (GS-800, Bio-
Rad, Munich, Germany).
2.4. Platelet membrane £uidity measurements and cytotoxicity assays
The e¡ects of EGCG (100 Wmol/l) on platelet membrane £uidity
were determined by measuring £uorescence anisotropy of the lipid
soluble £uorophore diphenylhexatriene (DPH) using a variable tem-
perature £uorescence polarization system (Beacon 2000, Panvera,
Madison, MI, USA) as previously described [20]. The e¡ects of
EGCG (100 Wmol/l) on the release of pre-loaded (30 min, 37‡C)
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calcein-AM (3 WM) from platelets was measured by £ow cytometry
[22].
2.5. Materials
Phospho-speci¢c antibodies against p38 mitogen-activated protein
kinase (MAPK) and extracellular signal-regulated kinases (ERK)-1
and -2 were from Cell Signaling Technology, Beverly, MA, USA.
Antibodies against phosphotyrosine (PY99), Syk (LR), LSP-76
(H-300), and phospho-focal adhesion kinase (FAK) (sc-11765-R)
were from Santa Cruz Biotechnology, Santa Cruz, CA, USA. Genis-
tein, herbimycin A, and PP2 were from Calbiochem-Novabiochem,
San Diego, CA, USA. K-Thrombin was a gift from Dr. J. Stu«rze-
becher (Erfurt, Germany). All other reagents were from Sigma,
Deisenhofen, Germany.
Fig. 1. E¡ects of various green tea catechins on thrombin (0.1 U/ml)-induced aggregation of washed human platelets. a: Original tracings, dem-
onstrating the concentration-dependent inhibition of platelet aggregation and shape change by EGCG. b: E¡ects of various catechins (100
Wmol/l) on thrombin-induced platelet aggregation (meansOS.E.M., n=5, *P6 0.05 versus control). c: Concentration-dependent inhibition of
platelet aggregation by EGCG (meansOS.E.M., n=5, *P6 0.05 versus control). d: Concentration-dependent inhibition of platelet aggregation
by GA (meansOS.E.M., n=5, *P6 0.05 versus control).
Fig. 2. E¡ects of EGCG (100 Wmol/l) on platelet signaling. a: Inhibition of thrombin (1 U/ml, 5 min)-induced phosphorylation of p38 MAPK
and ERK-1 and -2. b: E¡ects of EGCG on thrombin (1 U/ml, 5 min)-induced tyrosine phosphorylation of platelet proteins. c: Time course of
EGCG (100 Wmol/l)-induced tyrosine phosphorylation. d: E¡ects of EGCG (100 Wmol/l, 30 min) on tyrosine phosphorylation of Syk (IP, im-
munoprecipitation; WB, Western blot). e: E¡ects of EGCG (100 Wmol/l) on tyrosine phosphorylation of SLP-76 (IP, immunoprecipitation;
WB, Western blot). f : E¡ects of EGCG (100 Wmol/l) on (1 U/ml, 5 min) tyrosine phosphorylation of FAK. The blots shown are representative
of n=3^4 experiments.
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2.6. Statistics
Data are meanOS.E.M. of n independent experiments. Statistical
analysis was performed by one-way analysis of variance followed by
Bonferroni Multiple Comparisons test using GraphPad InStat version
3.01 for Windows 95 (GraphPad Software, San Diego, CA, USA).
P levels of 6 0.05 were considered signi¢cant.
3. Results
3.1. Inhibitory e¡ects of green tea catechins on thrombin-
induced platelet aggregation
EGCG concentration-dependently inhibited thrombin (0.1
U/ml)-induced platelet aggregation and shape change (Fig.
1a). A complete inhibition was seen at 100 Wmol/l EGCG
(Fig. 1c). These inhibitory e¡ects were time-dependent. Max-
imum inhibition was observed after 30 min of incubation time
(37‡C, unstirred conditions) (data not shown). EGCG also
concentration-dependently inhibited thrombin-induced exter-
nalization of CD62P, CD63 and CD40L as measured by £ow
cytometry (data not shown). Other green tea catechins (C,
EC, EGC, CG, ECG, 100 Wmol/l) did not inhibit platelet
aggregation (Fig. 1b). Some inhibition of thrombin-induced
platelet aggregation was observed with gallic acid (100
Wmol/l) (Fig. 1b,d).
3.2. E¡ects of EGCG on platelet signaling
EGCG (100 Wmol/l) largely inhibited thrombin (1 U/ml)-
induced phosphorylation of p38 MAPK and ERK-1 and -2
(Fig. 2a). In contrast, EGCG had complex e¡ects on throm-
bin (1 U/ml)-induced tyrosine phosphorylation of platelet pro-
teins. Thrombin-induced tyrosine phosphorylation of some
proteins (e.g. p115) was inhibited by EGCG. Surprisingly,
thrombin-induced tyrosine phosphorylation of other proteins
(e.g. p70, p76) was even higher after pre-incubation with
EGCG (Fig. 2b). Thus, the hypothesis was tested that
EGCG might directly stimulate tyrosine phosphorylation in
platelets. In fact, a stimulation of tyrosine phosphorylation by
EGCG was observed (Fig. 2c). These e¡ects consistently oc-
curred with 30 Wmol/l EGCG. In some experiments, however,
EGCG concentrations as low as 3 Wmol/l were e¡ective. In
contrast to thrombin, which very rapidly stimulates tyrosine
phosphorylation, the e¡ects of EGCG were slow with maxi-
mum phosphorylation at 10 min incubation time. Using im-
munoprecipitation, the tyrosine kinase Syk and the adapter
protein SLP-76 were identi¢ed to be tyrosine-phosphorylated
upon stimulation with EGCG (Fig. 2d,e). Using phospho-spe-
ci¢c antibodies, phosphorylation of FAK was shown to be
inhibited by EGCG in thrombin-stimulated platelets (Fig. 2f).
Fig. 3. Original tracings demonstrating the proaggregatory e¡ects of EGCG (30 Wmol/l) as compared to thrombin (0.1 U/ml).
Fig. 4. Direct e¡ects of various green tea catechins (100 WM) on platelet aggregation (left panels, meansOS.E.M., n=5) and tyrosine phosphor-
ylation (right panels, representative blots of n=5 experiments). Tyrosine phosphorylation was measured 15 min after addition of the catechins.
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3.3. Stimulatory e¡ects of green tea catechins on platelet
function
In initial experiments, where platelet aggregation was re-
corded for 4 min, no direct e¡ects of green tea catechins on
platelet aggregation were seen (data not shown). However,
because of the slow e¡ects of EGCG on tyrosine phosphory-
lation, additional aggregation experiments were carried out
with longer recording times. When EGCG was added to
stirred platelets, a stimulation of platelet aggregation was con-
sistently observed after about 10 min (Fig. 3). Although the
amplitude of the aggregation response varied, a clear aggre-
gation wave occurred in each single experiment. These activat-
ing e¡ects were observed with v 3 Wmol/l EGCG without a
clear concentration-dependency (Fig. 4). Interestingly, the two
other catechins containing a galloyl group in the 3P position
(CG, ECG) also stimulated platelet aggregation, while cate-
chins without a galloyl group (C, EC) or the catechin with a
galloyl group in the 2P position (EGC) did not. Gallic acid
was not e¡ective either (data not shown). In accordance with
these ¢ndings, the three catechins that stimulated platelet ag-
gregation (ECG, CG, EGCG) also stimulated tyrosine phos-
phorylation of platelet proteins (Fig. 4). EGC did stimulate
tyrosine phosphorylation but did not induce platelet aggrega-
tion. Nevertheless, we hypothesized that tyrosine phosphory-
lation might be involved in the proaggregatory e¡ects. In fact,
the src family protein tyrosine kinase inhibitors genistein (10
Wmol/l), herbimycin A (3 Wmol/l), and PP2 (10 Wmol/l) inhib-
ited EGCG (30 Wmol/l)- but not thrombin (0.1 U/ml)-induced
platelet aggregation (Fig. 5).
3.4. Possible non-speci¢c e¡ects of EGCG
EGCG (100 Wmol/l) did not change platelet membrane £u-
idity as measured by DPH £uorescence anisotropy. The mea-
surement of cytotoxicity by the MTT assay, as proposed by
Kang et al. [18], was not possible because EGCG resulted in a
strong color reaction even in the absence of cells. The same
applied to the XTT assay. However, EGCG did not a¡ect the
leakage of pre-loaded calcein, indicating the absence of cyto-
toxic e¡ects. More importantly, the inhibitory e¡ects of
EGCG were completely reversible when EGCG-treated plate-
lets were pelleted and resuspended in EGCG-free bu¡er. The
data are summarized in Fig. 6.
4. Discussion
The present study provides evidence for complex (inhibitory
and stimulatory) e¡ects of catechins on platelet function.
Platelet inhibitory e¡ects of EGCG have already been de-
scribed [17,18]. These e¡ects were explained by an inhibition
of cytoplasmic calcium increase [19]. In our study, ECGC was
shown to interrupt other signaling transduction pathways
such as phosphorylation of p38 MAPK or of ERK-1/2. In-
terestingly, none of the other major green tea catechins inhib-
ited platelet function and only small inhibitory e¡ects were
observed with high concentrations of gallic acid. Thus, the
present study is the ¢rst to demonstrate that only EGCG
appears to represent the active principle of platelet inhibitory
e¡ects of green tea catechins.
The e¡ects of EGCG were time-dependent with maximum
inhibition after 30 min of incubation time. This may explain
why in previous studies much higher concentrations of EGCG
were required to achieve an inhibitory e¡ect. The time-depen-
Fig. 5. Original tracings, demonstrating the e¡ects of the Src family
tyrosine kinase inhibitor PP2 (10 WM) on thrombin (1 U/ml)- and
EGCG (100 Wmol/l)-induced platelet aggregation. Similar ¢ndings
were observed with other tyrosine kinase inhibitors, including herbi-
mycin A (3 Wmol/l) or genistein (10 Wmol/l).
Fig. 6. Possible non-speci¢c e¡ects of EGCG. a: E¡ects of EGCG
(100 Wmol/l) on platelet membrane £uidity as determined by measur-
ing £uorescence anisotropy (mP) of the lipid soluble £uorophore
DPH (meansOS.E.M., n=3). b: E¡ects of EGCG (100 Wmol/l) on
the release of pre-loaded (30 min, 37‡C) calcein-AM (3 WM) from
platelets (meansOS.E.M., n=3). c: Original tracings, demonstrating
the reversibility of the inhibitory e¡ects of EGCG (100 Wmol/l) on
thrombin (0.1 U/ml)-induced platelet aggregation.
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dency of the anti-aggregatory e¡ects of EGCG might be ex-
plained by a time-dependent incorporation of the compound
into the platelet. Thus, one might speculate that other cate-
chins, such as CG or ECG, might also exhibit some inhibitory
e¡ects upon prolonged incubation. However, it was not pos-
sible to study this hypothesis because washed platelets have
only a limited viability. Importantly, the inhibitory e¡ects of
EGCG were not due to cytotoxicity because a full reversibility
of the aggregation response was observed upon removal of the
compound. In addition, no non-speci¢c e¡ects (e.g. alteration
of membrane £uidity) of EGCG were observed.
Some catechins from green tea have recently been shown to
inhibit tyrosine phosphorylation in vascular smooth muscle
cells [15]. Very similar ¢ndings have recently been reported
for catechins from red wine [24]. Thus, the hypothesis was
tested that this mechanism may explain the anti-aggregatory
e¡ects of EGCG. However, EGCG had complex e¡ects on
thrombin-induced tyrosine phosphorylation of platelet pro-
teins. Thrombin-induced tyrosine phosphorylation of some
proteins (e.g. p115) was inhibited by EGCG. Using phos-
pho-speci¢c antibodies, tyrosine phosphorylation of FAK
was demonstrated to be inhibited by EGCG. Since FAK is
involved in outside-in signaling [25], the inhibition of FAK
phosphorylation may contribute to the anti-aggregatory ef-
fects of this £avonoid.
Interestingly, thrombin-induced tyrosine phosphorylation
of some other proteins (e.g. p70, p76) was potentiated by
the compound. Therefore, possible direct stimulation of tyro-
sine phosphorylation by EGCG was studied. These experi-
ments clearly demonstrated that EGCG is able to directly
stimulate tyrosine phosphorylation of several proteins. Using
immunoprecipitation, the tyrosine kinase Syk and the adapter
protein SLP-76 were identi¢ed to be tyrosine-phosphorylated
upon stimulation with EGCG. Activation of Syk is necessary
for tyrosine phosphorylation of the adapter protein SLP-76.
This pathway is crucial for the activation of phospholipase
CQ2, which regulates [Ca2þ]i elevation and protein kinase C
activation [26^28].
The demonstration of stimulation of tyrosine phosphoryla-
tion of platelet proteins involved in platelet aggregation by
EGCG was a striking and unexpected ¢nding. Interestingly,
the stimulation of tyrosine phosphorylation by EGCG was
much slower as compared to other platelet stimuli, such as
thrombin. Therefore, in initial experiments, where platelet ag-
gregation was recorded for 4 min, no direct e¡ects of green tea
catechins on platelet aggregation were seen. However, when
the aggregation experiments were carried out with longer re-
cording times, EGCG consistently stimulated platelet aggre-
gation after about 10 min. Interestingly, the two other cate-
chins containing a galloyl group in the 3P position (CG, ECG)
also stimulated platelet aggregation, while catechins without a
galloyl group (C, EC) or the catechin with a galloyl group in
the 2P position (EGC) did not. Thus, although a di¡erent
e¡ect was measured in our study, the same structure^activity
relationship was observed as described for the inhibition of
the PDGF receptor phosphorylation by green tea catechins
[15].
Interestingly, the three catechins that stimulated platelet
aggregation (ECG, CG, EGCG) also stimulated tyrosine
phosphorylation of platelet proteins. However, EGC did
also stimulate tyrosine phosphorylation but did not induce
platelet aggregation. Nevertheless, we hypothesized that tyro-
sine phosphorylation might be involved in the proaggregatory
e¡ects of catechins. In fact, tyrosine kinase inhibitors inhib-
ited EGCG- but not thrombin-induced platelet aggregation. It
is di⁄cult to explain why the observed stimulation of tyrosine
phosphorylation by EGC does not translate to platelet aggre-
gation. One might speculate about additional inhibitory ef-
fects of EGC that may interfere with possible stimulatory
actions of the compound. In this context, it is noteworthy
that EGC was also active in inhibiting PDGF-induced smooth
muscle cell proliferation but did not inhibit PDGF receptor
phosphorylation [15], further supporting the view that addi-
tional actions of EGC actions might have prevented platelet
aggregation despite stimulation of tyrosine phosphorylation.
Similarly, the dual action of EGCG is di⁄cult to understand.
When incubated with unstirred platelets for 30 min, this cat-
echin inhibits thrombin-induced platelet signaling and aggre-
gation but exhibits stimulatory e¡ects when it is added to
platelets under stirring conditions. EGCG di¡ers from other
catechins in that this compound contains two galloyl groups.
Because high concentrations of gallic acid also inhibited plate-
let aggregation to some extent, this structure may be involved
in the inhibitory e¡ects of EGCG.
Taken together, all catechins containing a galloyl group
(EGC, ECG, CG, EGCG) did stimulate tyrosine phosphory-
lation of platelet proteins but only catechins containing the
galloyl group in the 3P position (ECG, CG, EGCG) stimu-
lated platelet aggregation. EGCG, a catechin containing two
galloyl groups, inhibited platelet function.
In summary, the present study demonstrated that green tea
catechins exhibit a variety of actions on human platelets.
Many mechanisms may contribute to the bene¢cial e¡ects of
catechins in atherosclerosis. The data presented in this study
do not exclude the possibility that inhibition of platelet func-
tion is one of these mechanisms. However, the demonstration
of stimulatory e¡ects on platelet aggregation and tyrosine
phosphorylation raises some concerns. Thus, further studies
are clearly needed before green tea or isolated catechins from
green tea can be generally recommended for prevention and/
or therapy of atherosclerosis.
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